2025
Phenotypic Selectivity of Artificial Intelligence-enhanced Electrocardiography in Cardiovascular Diagnosis and Risk Prediction.
Croon P, Dhingra L, Biswas D, Oikonomou E, Khera R. Phenotypic Selectivity of Artificial Intelligence-enhanced Electrocardiography in Cardiovascular Diagnosis and Risk Prediction. Circulation 2025 PMID: 40888124, DOI: 10.1161/circulationaha.125.076279.Peer-Reviewed Original ResearchElectronic health recordsNon-cardiovascular conditionsPhenome-wide association studyCross-sectional phenotypingNew-onset cardiovascular diseaseCardiovascular diseaseProspective cohort studyPhenotypic associationsHealth recordsLeft ventricular hypertrophyStructural heart diseaseAI-ECGAssociated with cardiovascular phenotypesPearson correlation coefficientDiagnosis codesCohort studyCardiovascular risk markersLogistic regressionAssociation studiesCardiovascular diagnosisMitral regurgitationAortic stenosisCardiovascular conditionsStudy populationDetection of LVSDArtificial intelligence-enabled electrocardiography and echocardiography to track preclinical progression of transthyretin amyloid cardiomyopathy
Oikonomou E, Sangha V, Vasisht Shankar S, Coppi A, Krumholz H, Nasir K, Miller E, Gallegos Kattan C, Al-Mallah M, Al-Kindi S, Khera R. Artificial intelligence-enabled electrocardiography and echocardiography to track preclinical progression of transthyretin amyloid cardiomyopathy. European Heart Journal 2025, ehaf450. PMID: 40679604, DOI: 10.1093/eurheartj/ehaf450.Peer-Reviewed Original ResearchTransthyretin amyloid cardiomyopathyTransthoracic echocardiographyATTR-CMAmyloid cardiomyopathyPreclinical progressAI-ECGRetrospective analysisDiagnosis of transthyretin amyloid cardiomyopathyDeep learning modelsAge/sex matched controlsRetrospective analysis of individualsLearning modelsPreclinical testingElectrocardiography imagingEchocardiographyHouston Methodist HospitalYale New Haven Health SystemAdvanced imagingElectrocardiographyPreclinical coursesCardiomyopathyPreclinical stage
2024
Artificial Intelligence–Enhanced Risk Stratification of Cancer Therapeutics–Related Cardiac Dysfunction Using Electrocardiographic Images
Oikonomou E, Sangha V, Dhingra L, Aminorroaya A, Coppi A, Krumholz H, Baldassarre L, Khera R. Artificial Intelligence–Enhanced Risk Stratification of Cancer Therapeutics–Related Cardiac Dysfunction Using Electrocardiographic Images. Circulation Cardiovascular Quality And Outcomes 2024, 18: e011504. PMID: 39221857, PMCID: PMC11745701, DOI: 10.1161/circoutcomes.124.011504.Peer-Reviewed Original ResearchCancer therapeutics-related cardiac dysfunctionGlobal longitudinal strainLeft ventricular systolic dysfunctionCardiac dysfunctionBreast cancerNon-Hodgkin lymphoma therapyNon-Hodgkin's lymphomaVentricular systolic dysfunctionAssociated with worse global longitudinal strainRisk stratification strategiesHigh-risk groupMonths post-treatmentPost Hoc AnalysisElectrocardiographic (ECGTrastuzumab exposureLymphoma therapySystolic dysfunctionAI-ECGBefore treatmentRisk biomarkersLongitudinal strainLow riskStratification strategiesHigher incidencePositive screen
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply